Guardant Health Statistics
Total Valuation
Guardant Health has a market cap or net worth of $21.31 billion. The enterprise value is $22.29 billion.
| Market Cap | 21.31B |
| Enterprise Value | 22.29B |
Important Dates
The last earnings date was Thursday, July 30, 2026, after market close.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Guardant Health has 134.20 million shares outstanding. The number of shares has increased by 4.62% in one year.
| Current Share Class | 134.20M |
| Shares Outstanding | 134.20M |
| Shares Change (YoY) | +4.62% |
| Shares Change (QoQ) | +1.21% |
| Owned by Insiders (%) | 3.54% |
| Owned by Institutions (%) | 99.05% |
| Float | 129.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.30 |
| Forward PS | 14.07 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 18.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.03
| Current Ratio | 4.03 |
| Quick Ratio | 3.53 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -97.65 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -18.07% |
| Return on Invested Capital (ROIC) | -23.43% |
| Return on Capital Employed (ROCE) | -29.89% |
| Weighted Average Cost of Capital (WACC) | 12.05% |
| Revenue Per Employee | $472,109 |
| Profits Per Employee | -$180,940 |
| Employee Count | 2,506 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 4.37 |
Taxes
| Income Tax | -1.03M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +283.46% in the last 52 weeks. The beta is 1.59, so Guardant Health's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | +283.46% |
| 50-Day Moving Average | 142.98 |
| 200-Day Moving Average | 107.79 |
| Relative Strength Index (RSI) | 58.47 |
| Average Volume (20 Days) | 2,194,869 |
Short Selling Information
The latest short interest is 11.42 million, so 8.51% of the outstanding shares have been sold short.
| Short Interest | 11.42M |
| Short Previous Month | 12.14M |
| Short % of Shares Out | 8.51% |
| Short % of Float | 8.82% |
| Short Ratio (days to cover) | 3.28 |
Income Statement
In the last 12 months, Guardant Health had revenue of $1.18 billion and -$453.44 million in losses. Loss per share was -$3.50.
| Revenue | 1.18B |
| Gross Profit | 769.16M |
| Operating Income | -469.03M |
| Pretax Income | -454.47M |
| Net Income | -453.44M |
| EBITDA | -431.80M |
| EBIT | -470.26M |
| Loss Per Share | -$3.50 |
Balance Sheet
The company has $1.05 billion in cash and $1.70 billion in debt, with a net cash position of -$643.54 million or -$4.80 per share.
| Cash & Cash Equivalents | 1.05B |
| Total Debt | 1.70B |
| Net Cash | -643.54M |
| Net Cash Per Share | -$4.80 |
| Equity (Book Value) | -222.87M |
| Book Value Per Share | -1.67 |
| Working Capital | 1.03B |
Cash Flow
In the last 12 months, operating cash flow was -$185.19 million and capital expenditures -$55.54 million, giving a free cash flow of -$240.72 million.
| Operating Cash Flow | -185.19M |
| Capital Expenditures | -55.54M |
| Depreciation & Amortization | 38.46M |
| Net Borrowing | 402.50M |
| Free Cash Flow | -240.72M |
| FCF Per Share | -$1.79 |
Margins
Gross margin is 65.01%, with operating and profit margins of -39.64% and -38.33%.
| Gross Margin | 65.01% |
| Operating Margin | -39.64% |
| Pretax Margin | -38.41% |
| Profit Margin | -38.33% |
| EBITDA Margin | -36.50% |
| EBIT Margin | -39.75% |
| FCF Margin | n/a |
Dividends & Yields
Guardant Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.62% |
| Shareholder Yield | -4.62% |
| Earnings Yield | -2.09% |
| FCF Yield | -1.11% |
Analyst Forecast
The average price target for Guardant Health is $187.50, which is 18.05% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $187.50 |
| Price Target Difference | 18.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 25 |
| Revenue Growth Forecast (3Y) | 35.67% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Guardant Health has an Altman Z-Score of 1.28 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.28 |
| Piotroski F-Score | 4 |